Intercept Pharmaceuticals
Income Statement
Last updated:
Income statement is a financial statement that shows how profitable a business was over a given reporting period presenting its revenue, expenses or net income. Intercept Pharmaceuticals's past years’ income statements indicate that its last revenue has decreased compared to the previous period by 21% to $285,710,000. The net income raised on $115,174,000 and profit margin reached 40%. Total operating expenses were $352,942,000.
Profit Margin
| 2013 | 1.62M | -67.79M | -4180.52% |
|---|---|---|---|
| 2014 | 1.74M | -283.22M | -16258.67% |
| 2015 | 2.78M | -226.42M | -8139.07% |
| 2016 | 24.95M | -412.83M | -1654.56% |
| 2017 | 130.95M | -360.36M | -275.18% |
| 2018 | 179.80M | -309.24M | -171.99% |
| 2019 | 252.00M | -391.05M | -155.18% |
| 2020 | 312.69M | -324.23M | -103.69% |
| 2021 | 363.46M | -145.02M | -39.9% |
| 2022 | 285.71M | 115.17M | 40.31% |
ICPT Income Statement (2013 – 2022)
| 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | |
|---|---|---|---|---|---|---|---|---|---|---|
Revenue | ||||||||||
Revenue | 285.71M | 363.46M | 312.69M | 252.00M | 179.80M | 130.95M | 24.95M | 2.78M | 1.74M | 1.62M |
Cost of revenue | 984K | 3.1M | 5.32M | 4.21M | 2.51M | 1.37M | 0 | 0 | 0 | 0 |
Gross profit | 284.72M | 360.36M | 307.36M | 247.79M | 177.28M | 129.58M | 24.95M | 2.78M | 1.74M | 1.62M |
Operating exp. | ||||||||||
Research and development | 176.63M | 185.27M | 191.48M | 242.79M | 207.30M | 191.49M | 153.89M | 128.19M | 80.31M | 27.94M |
Selling and marketing | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Total operating expenses | 352.94M | 416.12M | 523.97M | 560.21M | 462.77M | 465.19M | 427.48M | 231.93M | 114.91M | 41.07M |
Operating income | -68.21M | -55.75M | -216.61M | -312.42M | -285.49M | -335.61M | -402.53M | -229.15M | -113.17M | -39.45M |
Other income (expenses), net | -106.64M | -35.66M | -43.64M | -32.25M | 6.77M | -24.75M | 3.90M | 2.72M | -170.05M | -28.34M |
Income before tax | -174.85M | -91.42M | -274.88M | -344.68M | -309.24M | -360.36M | -412.83M | -226.42M | -283.22M | -67.79M |
Income tax expense | -290.03M | 53.59M | 49.35M | 46.37M | 6.77M | 29.18M | 14.26M | 1.03M | 170.38M | 28.44M |
Net income | 115.17M | -145.02M | -324.23M | -391.05M | -309.24M | -360.36M | -412.83M | -226.42M | -283.22M | -67.79M |
Earnings per share | ||||||||||
Basic EPS | 3.41 | -4.55 | -9.83 | -12.35 | -10.86 | -14.38 | -16.74 | -9.56 | -13.63 | -3.76 |
Diluted EPS | 3.4 | -4.55 | -9.83 | -12.35 | -10.86 | -14.38 | -16.74 | -9.56 | -13.63 | -3.76 |
| Data source | Data source | Data source | Data source | Data source | Data source | Data source | Data source | Data source | Data source |